Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
Clinical trial NCT05328102 · TERMINATED
Trial details
- NCT number
- NCT05328102
- Sponsor
- Xencor, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-04-15
- Primary completion
- 2023-02-21
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.